Platelet-activating factor. A potent chemotactic and chemokinetic factor for human eosinophils. (original) (raw)
Find articles by Wardlaw, A. in:[JCI](/search/results?q=author.first%5Fname%3A%22A J%22+author.last%5Fname%3A%22Wardlaw%22&search%5Ftype=advanced) |PubMed |Google Scholar
Find articles by Moqbel, R. in:JCI |PubMed |Google Scholar
Find articles by Cromwell, O. in:JCI |PubMed |Google Scholar
Find articles by Kay, A. in:[JCI](/search/results?q=author.first%5Fname%3A%22A B%22+author.last%5Fname%3A%22Kay%22&search%5Ftype=advanced) |PubMed |Google Scholar
Published December 1, 1986 -Version history
Platelet-activating factor (PAF-acether), an inflammatory mediator with a wide range of biological activities including neutrophil aggregation and chemotaxis, was studied for its effect on human eosinophil locomotion (chemotaxis and chemokinesis). Human eosinophils (25-95% purity) were obtained from donors with a variety of diseases associated with hypereosinophilia. PAF-acether elicited directional locomotion of eosinophils, in a time- and dose-dependent fashion, at concentrations from 10(-5) to 10(-8) M; lyso-PAF had minimal activity over the same dose range. Compared with PAF-acether, the eosinophil locomotory responsiveness of leukotriene B4 (LTB4), histamine, and the valyl- and alanyl-eosinophil chemotactic factor of anaphylaxis (ECF-A) tetrapeptides was negligible. Conversely, neutrophil responsiveness to PAF-acether (optimum 10(-6) M) was comparable in effect to LTB4 (optimum dose 10(-8) M). It was shown that PAF-acether elicited both chemotaxis and chemokinesis of eosinophils. Comparison of normal density and light density eosinophils revealed no qualitative difference in the response to PAF-acether and the other chemoattractants, although the light density cells seemed to demonstrate a greater degree of locomotion to PAF-acether and LTB4. Thus, PAF-acether appears to be a potent eosinophilotactic agent which may play a role in inflammatory reactions characterized by eosinophil infiltration.
Click on an image below to see the page. View PDF of the complete article